Table 1.
Patient | Gender | Age (years) | PB or BM | FAB | Karyotype |
---|---|---|---|---|---|
AML P1 | F | 79 | BM | M2 | Normal |
AML P2 | M | 53 | BM | M1 | Normal |
AML P3 | F | 77 | PB | M6 | 46, XX, t(5;17) |
AML P4 | F | 78 | PB | M1 | Normal |
AML P5 | M | 63 | PB | M5a | 46, XY/73–78, XXXY, 1q-(3:14) |
AML P6 | M | 62 | PB | Sec AML | Normal |
AML P7 | M | 62 | PB | M2 | 46, XY, der(17) t(8;17) |
AML P8 | M | 77 | BM | Sec AML | 46, XY, t(9;22) |
AML P9 | M | 75 | BM | M5b | 47, XY, +8, add(10)(p15) |
AML P10 | M | 77 | BM | M2 | Normal |
AML P11 | F | 73 | PB | M5b | Normal |
AML P12 | M | 23 | BM | M2 | Normal |
AML P13 | M | 69 | PB/BM | M5a | Normal |
AML P14 | M | 36 | PB/BM | M2 | Normal |
AML P15 | M | 71 | PB | M2 | Normal |
AML P16 | M | 62 | PB | M2 | Normal |
AML P17 | F | 71 | PB | Sec AML | Normal |
AML P18 | F | 25 | PB | M5a | Normal |
AML P19 | M | 30 | PB | M3 | Normal |
AML P20 | F | 67 | BM | M2 | 46, XX, del(5q) |
AML P21 | F | 61 | BM | M2 | 46, XX, inv(16) |
Abbreviations: M, male; F, female; PB, peripheral blood; BM, bone marrow; FAB, French–American–British classification system; Sec AML, secondary AML